中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner

文献类型：期刊论文

作者Wu, Yao6; Du, Hongzhi2; Zhan, Meixiao7; Wang, Hongxv6; Chen, Peng5; Du, Danyu6; Liu, Xinyi1; Huang, Xingxv1; Ma, Pengcheng4; Peng, Dezheng4
刊名CELL DEATH & DISEASE
出版日期2020-04-20
卷号11期号:4页码:14
ISSN号2041-4889
DOI10.1038/s41419-020-2471-7
通讯作者Ding, Jian(jding@simm.ac.cn) ; Lu, Ligong(luligong1969@126.com) ; Jiang, Jingwei(jiangjingwei@cpu.edu.cn)
英文摘要Sepiapterin reductase plays an enzymatic role in the biosynthesis of tetrahydrobiopterin, which is reported in limited studies to regulate the progression of several tumors. However, the role of sepiapterin reductase in hepatocellular carcinoma remains largely unknown. Here, we found that sepiapterin reductase was frequently highly expressed in human hepatocellular carcinoma, which was significantly associated with higher T stage, higher tumor node metastasis stage, and even shorter survival of hepatocellular carcinoma patients. Furthermore, cell and animal experiments showed that sepiapterin reductase depletion inhibited cancer cell proliferation and promoted cancer cell apoptosis. Importantly, the results suggested that sepiapterin reductase enzymatic activity was not necessary for the progression of hepatocellular carcinoma, based on the comparison between SMMC-7721 and SMMC-7721 containing sepiapterin reductase mutant. Moreover, we showed that sepiapterin reductase regulated the development of hepatocellular carcinoma via the FoxO3a/Bim-signaling pathway. Collectively, our study suggests that sepiapterin reductase controls hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner, which provides a potential prognostic factor and therapeutic strategy for hepatocellular carcinoma.
WOS关键词CANCER-CELL MIGRATION ; TETRAHYDROBIOPTERIN ; BIM ; GROWTH ; PROLIFERATION ; REVEALS ; TARGET ; LSD1
资助项目National Key Research and Development Program of China[2017YFA0205200] ; National Natural Science Foundation of China[81773766] ; National Natural Science Foundation of China[81903845] ; Science and Technology Research Project of Hubei Provincial Department of Education[Q20192007] ; Natural Science Foundation of Jiangsu Province[SBK2018021376] ; Double First-Class University project[CPU2018GY38] ; Graduate Student Research Innovation Projects in Jiangsu Province[KYCX17_0691]
WOS研究方向Cell Biology
语种英语
WOS记录号WOS:000529212000003
出版者NATURE PUBLISHING GROUP
源URL[http://119.78.100.183/handle/2S10ELR8/280584]  
专题新药研究国家重点实验室
通讯作者Ding, Jian; Lu, Ligong; Jiang, Jingwei
作者单位1.ShanghaiTech Univ, Sch Life Sci & Technol, 100 Haike Rd, Shanghai, Peoples R China
2.Hubei Univ Chinese Med, Sch Pharm, 16 Huangjiahu Rd West, Wuhan, Peoples R China
3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China
4.Peking Union Med Coll, Chinese Acad Med Sci, Inst Dermatol, 12 Jiangwangmiao St, Nanjing, Peoples R China
5.Nanchang Univ, Dept Neurosurg, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
6.China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, Nanjing, Peoples R China
7.Jinan Univ, Zhuhai Hosp, Zhuhai Peoples Hosp, Zhuhai Intervent Med Ctr,Zhuhai Precis Med Ctr, Zhuhai, Peoples R China
推荐引用方式
GB/T 7714		 Wu, Yao,Du, Hongzhi,Zhan, Meixiao,et al. Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner[J]. CELL DEATH & DISEASE,2020,11(4):14.
APA Wu, Yao.,Du, Hongzhi.,Zhan, Meixiao.,Wang, Hongxv.,Chen, Peng.,...&Jiang, Jingwei.(2020).Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner.CELL DEATH & DISEASE,11(4),14.
MLA Wu, Yao,et al."Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner".CELL DEATH & DISEASE 11.4(2020):14.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。